Pharmafile Logo
Pharmafocus logo
Advanced Search

Meridia

Showing 3 posts of 3 posts found.

Obesity

Takeda obesity drug falters at phase II

March 18, 2011
Research and Development Alli, Amylin, Contrave, Meridia, Qnexa, Takeda, Xenical, lorcaserin, metreleptin, obesity, pramlintide

Yet another investigational drug appears to have faltered on the rocky path to develop anti-obesity treatments. Takeda Pharmaceutical Company and …

News

Abbott withdraws anti-obesity drug amid safety worries

October 11, 2010
Sales and Marketing Abbott, Meridia, obesity

Abbott has pulled its anti-obesity drug Meridia in the US after recent trials showed it increased the risk of stroke …

News
Abbott Park

Abbott’s Meridia ‘increases heart attack risk’

September 2, 2010
Sales and Marketing Abbott, Meridia, drug safety

Abbott’s weight-loss drug Meridia increases the risk of stroke and heart attack in patients with heart disease, according a study …

News

Latest content

Sanofi shares results from phase 2 trial for frexalimab in MS treatment

July 1, 2024

EMA accepts AstraZeneca’s regulatory submission for sipavibart for COVID-19 prevention

July 1, 2024

Eisai and Biogen’s Leqembi launched for Alzheimer’s treatment in China

June 28, 2024

AbbVie’s Tepkinly gains positive CHMP opinion for follicular lymphoma treatment

June 28, 2024

IDEAYA Biosciences announces first-patient-in for phase 1 clinical trial evaluating IDE397 and Trodelvy combination in MTAP-deletion bladder cancer

June 27, 2024